Wie sind die Öffnungszeiten?

Montag 09:00 - 17:00 Dienstag 09:00 - 17:00 Mittwoch 09:00 - 17:00 Donnerstag 09:00 - 17:00 Freitag 09:00 - 17:00

Cutiss AG, Grabenstrasse 11, Schlieren, Zürich (2026)

Name: Cutiss AG
Address: Grabenstrasse 11, Schlieren, Zürich, 8952, CH
Telephone: +41435492110

Swiss life sciences company focussed on skin regenerative medicine & tissue engineering - developing the world's first personalised & automated skin tissue therapy for patients with severe burns and skin injuries CUTISS is a Swiss clinical-stage life sciences company focussed on skin regenerative medicine and tissue engineering. It is developing the first personalised and automated skin tissue the

rapy offering life-saving and life-changing medical treatments for patients with severe skin injuries. The lead product denovoSkin promises to take skin surgery to the next level and revolutionise current treatments. It is a bio-engineered and personalised dermo-epidermal human skin graft, currently in Phase IIb clinical trials in Switzerland and the European Union, with Orphan Drug Designation for the treatment of burns from Swissmedic, EMA, and FDA. CUTISS is also developing the world’s first machine that can automate the entire production process of the personalised skin graft. The company’s knowledge in skin bio-engineering and biology offers several growth opportunities in regenerative medicine. Established in 2017, the company is a spin-off from University of Zurich (UZH) / University Children’s Hospital and a member of the accelerator Wyss Zurich. Headquartered at the Bio-Technopark in Zurich, it won the Top 100 Swiss Startup Award 2020, and has raised about CHF 50 million from private investors, family offices and public bodies.

23/06/2026

CUTISS has announced today the election of Dr. Achim von Leoprechting as Chairman of its Board, as the company prepares for its next phase of growth.

Dr. von Leoprechting brings more than 25 years of international leadership experience across life sciences, diagnostics, medical device markets and laboratory automation, with a strong track record in scaling global operations. He most recently served as CEO of Tecan.

He succeeds Prof. Dr. med. Martin Meuli, co-founder of CUTISS, who has chaired the Board since the company’s foundation in 2017 and supported its development from a university spin-off into a late-stage clinical company. Prof. Meuli remains a member of the Board.

This Board transition comes as CUTISS continues to advance denovoSkin™, its personalized, bioengineered skin tissue therapy, and prepares for its upcoming milestones.

You can find the full announcement here: https://cutiss.swiss/dr-achim-von-leoprechting-elected-chairman-of-cutiss-board-of-directors/

18/03/2026

This month we celebrated the 9th birthday of CUTISS!

Our amazing team was able to mark this milestone in a particularly meaningful way, together with our medical trainers and many of the clinical investigators and their teams involved in our ongoing Phase 3 trial who travelled to Zurich from 7 different EU countries for 2 days of workshops, networking and discussions.

Our progress is the result of a shared effort between CUTISS’ team, surgeons, clinical teams, researchers, partners (including Tecan and Rode Kruis Ziekenhuis) and patients. Their trust and dedication honor us and give us an amazing motivation to keep pushing the boundaries in skin surgery.

As our Phase 3 study of denovoSkin™ and our automation program continue, we remain focused on developing a personalized, scalable and accessible skin tissue therapy that can significantly improve outcomes for patients with severe skin injuries and reduce the burden of today’s standard treatments.

We have our goals in sight, and we remain committed to make our therapy available to as many patients, as soon as possible

04/12/2025

A major step forward in personalized skin tissue therapy: we’re excited to share that the 1-year results from our Phase 2 clinical trial of denovoSkin™ have now been published in eClinicalMedicine (The Lancet Discovery Science).

The results demonstrate safety and – in sharp contrast to the intra-patient autografting control – a significantly reduced need for donor-site harvesting together with minimal scarring.

These outcomes reinforce the potential of denovoSkin™ to safely spare donor sites, improve long-term healing, and offer a new therapeutic path for patients with severe burns.

While the paper reports the 1-year results, the clinical follow-up for this study has now been completed through 3 years, further enriching our long-term data.

In parallel, our Phase 2 pediatric burn study is ongoing and will soon reach its 1-year readout, the reconstructive Phase 2 trial is nearing its 2-year readout, and our Phase 3 trial continues to progress in the EU and Switzerland.

24/11/2025

🎥 Our mission: revolutionizing skin surgery through personalized regenerative medicine.

This video was created following our 2nd place at The Spark – Der Deutsche Digitalpreis 2025 — the first time a Swiss company has received this recognition.

At CUTISS, we’re developing denovoSkin™, a personalized, bio-engineered human skin graft for patients with severe skin injuries. By combining bioengineering with automation, we’re scaling the future of skin tissue therapy.

10/11/2025

🏆 CUTISS takes 2nd place at The Spark Award 2025 – and makes Swiss history!

We’re proud that CUTISS has been awarded 2nd place at this year’s The Spark – Der Deutsche Digitalpreis, recognizing breakthrough deep-tech innovation across Germany, Austria, and Switzerland. What an incredible evening in Munich last week!

This also marks the first time a Swiss company has received an award at The Spark. It has been an honor to represent Swiss tech and regenerative medicine innovation amongst the inspiring group of finalists.

A big thank you to Handelsblattt and McKinsey & Company for continuing to organize this award over 10 years, and of course to everyone who supported and voted for us along the way.

Shout out and congratulations to Black Semiconductor for winning their well-deserved first place!

Photos credit © Marc-Steffen Unger for Handelsblatt.

Adresse

Grabenstrasse 11, Schlieren
Zürich
8952

Öffnungszeiten

Montag	09:00 - 17:00
Dienstag	09:00 - 17:00
Mittwoch	09:00 - 17:00
Donnerstag	09:00 - 17:00
Freitag	09:00 - 17:00

Telefon

+41435492110

Webseite

http://www.cutiss.swiss/

Benachrichtigungen

Lassen Sie sich von uns eine E-Mail senden und seien Sie der erste der Neuigkeiten und Aktionen von Cutiss AG erfährt. Ihre E-Mail-Adresse wird nicht für andere Zwecke verwendet und Sie können sich jederzeit abmelden.

Cutiss AG